论文部分内容阅读
目的探讨康莱特辅助治疗非小细胞肺癌的临床效果。方法将我院接诊的47例非小细胞肺癌患者纳入本研究。随机分为观察组24例和对照组23例。对照组:吉西他滨+顺铂。观察组:在对照组治疗的基础上,采取康莱特治疗。观察患者疾病控制率、不良反应发生情况。结果观察组疾病控制率为83.33%,高于对照组的56.56%,差异有统计学意义(P<0.05),观察组不良反应总发生率为20.83%,低于对照组的65.22%,差异有统计学意义(P<0.05)。结论康莱特辅助治疗非小细胞肺癌效果较好,患者疾病控制率高,不良反应少,临床应用价值高。
Objective To investigate the clinical effect of Kanglaite adjuvant therapy for non-small cell lung cancer. Methods 47 cases of non-small cell lung cancer admitted to our hospital were included in this study. Randomly divided into observation group 24 cases and control group 23 cases. Control group: Gemcitabine + cisplatin. Observation group: On the basis of the control group, KLT was taken. Observe the disease control rate, the occurrence of adverse reactions. Results The disease control rate in the observation group was 83.33%, which was higher than 56.56% in the control group (P <0.05). The total incidence of adverse reactions in the observation group was 20.83%, which was lower than 65.22% in the control group. The difference was Statistical significance (P <0.05). Conclusions Kanglaite adjuvant treatment of non-small cell lung cancer better, patients with high disease control, fewer adverse reactions, clinical application of high value.